The Supreme Court resurrected two whistleblower lawsuits against companies for allegedly defrauding Medicare and Medicaid. The cases concern the federal False Claims Act (FCA), a key tool the government uses to combat health care fraud, and “scienter,” a legal term meaning prior intent or knowledge of wrongdoing. Sen. Charles Grassley (R) has called the FCA…

“The upper bounds of damages against Pfizer would be $3.6 trillion dollars. And obviously, Pfizer’s not worth $3.6 trillion dollars. That company would have to be seized in bankruptcy, its assets distributed and sold off, and I think that’s an appropriate end for that company. So I’m doing everything I can to get there.” After…

“The upper bounds of damages against Pfizer would be $3.6 trillion dollars. And obviously, Pfizer’s not worth $3.6 trillion dollars. That company would have to be seized in bankruptcy, its assets distributed and sold off, and I think that’s an appropriate end for that company. So I’m doing everything I can to get there.” After…

“The upper bounds of damages against Pfizer would be $3.6 trillion dollars. And obviously, Pfizer’s not worth $3.6 trillion dollars. That company would have to be seized in bankruptcy, its assets distributed and sold off, and I think that’s an appropriate end for that company. So I’m doing everything I can to get there.” After…

“The upper bounds of damages against Pfizer would be $3.6 trillion dollars. And obviously, Pfizer’s not worth $3.6 trillion dollars. That company would have to be seized in bankruptcy, its assets distributed and sold off, and I think that’s an appropriate end for that company. So I’m doing everything I can to get there.” After…

The Supreme Court ruled 8–1 that the U.S. Department of Justice is allowed to seek dismissal of a whistleblower lawsuit over the objection of a whistleblower who has a financial interest in the outcome of the lawsuit. Justice Elena Kagan wrote the court’s majority opinion (pdf) in United States ex rel. Polansky v. Executive Health…